$102.860
+2.047 (+1.99%)收盘时
NRG 资讯
NRG 事件
PDS Biotechnology Borrow Rate Increases to 10.40%
Latest data shows the largest indicative borrow rate increases among liquid option names include: PDS Biotechnology Corp (PDSB) 10.40% +6.80, Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.22% +3.70, NRG Energy (NRG) 3.68% +3.27, Ruger (RGR) 5.77% +1.24, ProShares Trust (SPCF) 36.46% +0.37, Arbutus Biopharma (ABUS) 1.21% +0.25, ISHARES ETHEREUM TRUST ETF (ETHA) 0.68% +0.22, Astex Pharmaceuticals Inc (ASTX) 6.60% +0.21, Rezolve AI Ltd (RZLV) 21.51% +0.21, and MercadoLibre (MELI) 0.55% +0.19.
Constellation Energy Gains $41.50 to $309.12
Notable gainers among liquid option names this morning include Constellation Energy (CEG) $309.12 +41.50, Vistra Energy (VST) $160.09 +15.20, Corteva (CTVA) $13.66 +1.27, NRG Energy (NRG) $104.74 +7.94, and Marvell (MRVL) $292.48 +21.23.
TD Cowen: FERC Delays PJM Reliability Procurement, Affects Multiple Companies
TD Cowen energy policy analyst John Miller notes that the Federal Energy Regulatory Commission last night issued an order on PJM Interconnection's reliability backstop procurement filing. FERC accepted core framework but found cost allocation to be potentially unjust and unreasonable, the analyst tells investors in a research note. The agency suspended the filing for five months subject to a paper hearing, TD adds. The firm says FERC's order again delays the entire reliability backstop procurement timeline. It sees "renewed (and acute) uncertainty here as negative for all involved." Shares of Constellation Energy (CEG), NRG Energy (NRG) and Talen Energy (TLN) are moving lower in Wednesday trading.
NRG Reports Q2 Revenue of $7.481B
Reports Q2 revenue $7.481B, consensus $7.79B. "Today we provided a progress update on our Bring Your Own Power data center strategy," said Robert Gaudette, President & CEO. "This is the model for how large load growth should work. The customer supports the investment, with reliability and affordability protected for all. We also delivered a solid second quarter and are reaffirming our 2026 guidance. I am confident in the discipline and execution that continue to drive NRG forward."
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。









